Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …

Purpose Ferroptosis is a new mode of regulated cell death, which is completely distinct from
other cell death modes based on morphological, biochemical, and genetic criteria. This …

Purpose: KRAS mutations occur in approximately 25% of patients with non–small cell lung
cancer (NSCLC). Despite the uniform presence of KRAS mutations, patients with KRAS …

KRAS is the most frequently mutated oncogene in human cancer. In addition to holding this
distinction, unsuccessful attempts to target this protein have led to the characterization of …

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …

Somatic mutations in the small GTPase K-Ras are the most common activating lesions found
in human cancer, and are generally associated with poor response to standard therapies …

Cancer therapy has traditionally focused on eliminating fast-growing populations of cells.
Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can …

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …